La anemia en la leucemia linfática crónica¿es la eritropoyetina la solución del problema?

1. Ruiz de Gaona Lana, Estefania
2. Rifón Roca, José Juan
3. Pérez-Calvo, J.
4. Bendandi, Maurizio
5. C. Panizo
6. Iglesias del Barrio, R.

Esportatu

Esportatu

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Esportatu

×

Dokumentua ezin da beste atari batetik esportatu.

Testu osoa

lock_openTestu osoa externo

DIALNET GOOGLE SCHOLAR lock_openSarbide irekia editor

Laburpena

Anemia is a common complication in the clinical course of chronic lymphocytic leukemia. Low hemoglobin levels both correlate with an adverse prognosis and adversely affect the quality of life of chronic lymphocytic leukemia patients. Different physiopathological phenomena may lead to anemia: marrow infi ltration, hypersplenism, immune hemolysis or toxicity of chemotherapy. Treatment with human recombinant erythropoietic agents has been shown to be effective for anemia associated with different lymphoproliferative syndromes. This paper analyses the available evidence on erythropoietic agent treatment for chronic lymphocytic leukemia associated anemia. The comparative effect of different dosage schemes, the role of possible response-prediction factors such as the endogenous erythropoietin level and the results achieved using darbopoietin alpha are reviewed.

Datuen iturria: Dialnet